Current Report Filing (8-k)
March 09 2017 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 9, 2017
Mirati Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35921
|
|
46-2693615
|
(State of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
9393 Towne Centre Drive, Suite 200
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (858) 332-3410
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On March 9, 2017, Mirati
Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter ended December 31, 2016. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated March 9, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: March 9, 2017
|
|
|
|
M
IRATI
T
HERAPEUTICS
, I
NC
.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jamie A. Donadio
|
|
|
|
|
|
|
Jamie A. Donadio
|
|
|
|
|
|
|
Senior Vice President and Chief Financial Officer
|
INDEX TO EXHIBITS
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated March 9, 2017.
|
Mirati Therapeutics (NASDAQ:MRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirati Therapeutics (NASDAQ:MRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024